This study finds that the Comprehensive and Economic Trade Agreement (CETA) between the European Union and Canada will further tilt the balance towards the protection of brand-name drug manufacturers and their profits and away from Canadian consumers—resulting in significantly higher drug costs for Canadians. The study also examines the latest revelations about the tentative trade agreement, and asserts that the CETA will seriously impact the ability of Canadians to afford quality health care.
CETA and Pharmaceuticals
Impact of the trade agreement between Europe and Canada on the costs of patented drugs
October 31, 2013